A phase I, open-label, randomized, three-way crossover trial evaluating the efficacy, safety, pharmacokinetics and tolerability of two fixed-dose combinations (FDC) of Darunavir/Cobicistat (G003 and G004) versus Darunavir and Ritonavir in healthy volunteers.

Trial Profile

A phase I, open-label, randomized, three-way crossover trial evaluating the efficacy, safety, pharmacokinetics and tolerability of two fixed-dose combinations (FDC) of Darunavir/Cobicistat (G003 and G004) versus Darunavir and Ritonavir in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2015

At a glance

  • Drugs Cobicistat/darunavir (Primary) ; Darunavir; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms TMC114IFD1001
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top